Dr. Mark Feinberg

Mark Feinberg MD, PhD is President and CEO of IAVI where he leads a global team working to advance the development of vaccines and other biomedical innovations to protect against infection with HIV, TB, emerging zoonotic viruses and other infectious diseases that disproportionately impact low-income countries. He is a physician-scientist who has been actively engaged in basic, translational and clinical research, and patient care and health care policy. Mark received his BA degree from the University of Pennsylvania and MD and PhD degrees from Stanford Medical School. He pursued postgraduate medical training in Internal Medicine at the Brigham and Women’s Hospital of Harvard Medical School and a postdoctoral fellowship in the laboratory of David Baltimore at the Whitehead Institute for Biomedical Research. Mark has previously served on the faculty of the University of California, San Francisco and the Emory University School of Medicine, and as a Medical Officer in the Office of AIDS Research at the National Institutes of Health (NIH). Between 2004-2015, he was Chief Public Health and Science Officer for Merck Vaccines where he led coordination of multiple collaborative R&D initiatives focused on addressing global health challenges, including the public-private partnership to enable the accelerated development of the VSV-ZEBOV Ebola vaccine. Mark played a central role in the establishment of the Coalition for Epidemic Preparedness Innovations (CEPI) and served as Chair of the CEPI’s Interim Scientific Advisory Committee. Mark is a Fellow of the American College of Physicians and member of the Association of American Physicians and the Council on Foreign Relations.